FDA grants expanded approval for Bristol Myers Squibb anemia therapy - NJBIZ

“The approval of Reblozyl in the first-line treatment of anemia for patients with lower-risk MDS represents a crucial step in making transfusion independence possible for more patients," said Tracey Iraca, executive director of the MDS Foundation.

U.S. FDA approves new Bristol Myers cancer immunotherapy

FDA expands Reblozyl approval to first-line use - Drug Discovery World (DDW)

Making a list - NJBIZ

U.S. FDA Approves Bristol Myers Squibb's Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions

FDA Grants Priority Review to BMS' Supplemental BLA for Breyanzi

Bristol Myers Squibb - Recent News & Activity

Prism launches construction for Woodbridge transit-oriented community - NJBIZ

Celgene nabs FDA approval for blockbuster hopeful anemia med Reblozyl

Cushman & Wakefield named exclusive agent for Morristown office asset - NJBIZ

US FDA to delay decision on Bristol Myers-2seventy bio cancer therapy

Bristol Myers Squibb - U.S. FDA Approves Bristol Myers Squibb's Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions

FDA expands Reblozyl approval to first-line use - Drug Discovery World (DDW)

Murphy signs bill expanding definition of qualified offshore wind project - NJBIZ

Four NJ entities to lead new pediatric payment model with $15.8M CMS award - NJBIZ

Bristol Myers Squibb - U.S. FDA Approves Bristol Myers Squibb's Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions